Association of genetic polymorphisms in MDM2, PTEN and P53 with risk of esophageal squamous cell carcinoma

Journal of Human Genetics

Volumn 57, Issue 4, 2012, Pages 261-264

  Ma, Juan ^a   Zhang, Jianna ^a   Ning, Tao ^b   Chen, Ziping ^a   Xu, Changqing ^a  

^a SHANDONG UNIVERSITY   (China)

^b CANCER HOSPITAL   (China)

Author keywords

esophageal squamous cell carcinoma; MDM2; P53; polymorphism; PTEN

Indexed keywords

ARGININE; GENOMIC DNA; PROLINE;

AMINO ACID SUBSTITUTION; ARTICLE; CANCER RISK; CHINESE; CONTROLLED STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MDM2 GENE; P53 GENE; POLYMERASE CHAIN REACTION; PTEN GENE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TUMOR SUPPRESSOR GENE;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; ESOPHAGEAL NEOPLASMS; FEMALE; GENE FREQUENCY; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROTO-ONCOGENE PROTEINS C-MDM2; PTEN PHOSPHOHYDROLASE; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84860274999     PISSN: 14345161     EISSN: 1435232X     Source Type: Journal    
DOI: 10.1038/jhg.2012.15     Document Type: Article

References (30)

1. Momand, J., Zambetti, G. P., Olson, D. C., George, D. & Levine, A. J. The mdm2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 69, 1237-1245 (1992).
2. Haupt, Y., Maya, R., Kazaz, A. & Oren, M. Mdm2 promotes the rapid degradation of p53. Nature. 387, 296-299 (1997). (Pubitemid 27220766)
3. Yin, Y. & Shen, W. H. PTEN: A new guardian of the genome. Oncogene. 27, 5443-5453 (2008).
4. Lindsey, D. M., Jack, E. D., Donald, L. D., Nickolas, K. T. & David, B. D. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J. Biol. Chem. 277, 5484-5489 (2002).
5. Lindsey, D. M. & David, B. D. The PTEN, MDM2, P53 tumor suppressor oncoprotein network. Trends. Biochem. Sci. 27, 9 (2002).
6. Bond, G. L., Hu, W., Bond, E. E., Robins, H., Lutzker, S. G., Arva, N. C. et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 119, 591-602 (2004). (Pubitemid 39535748)
7. Bond, G. L., Hu, W. & Levine, A. A single nucleotide polymorphism in the MDM2 gene: From a molecular and cellular explanation to clinical effect. Cancer. Res. 65, 5481-5484 (2005). (Pubitemid 40911143)
8. Ohmiya, N., Taguchi, A., Mabuchi, N., Itoh, A., Hirooka, Y., Niwa, Y. et al. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J. Clin. Oncol. 24, 4434-4440 (2006). (Pubitemid 46630981)
9. Dumont, P., Leu, J. I., Della, A. C., George, D. L. & Murphy, M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet. 33, 357-365 (2003). (Pubitemid 36278852)
10. Chang, F., Syrjänen, S., Wang, L. & Syrjänen, K. Infectious agents in the etiology of esophageal cancer. Gastroenterology 103, 1136-1148 (1992).
11. Hiyama, T., Yoshihara, M., Tanaka, S. & Chayama, K. Genetic polymorphisms and esophageal cancer risk. Int. J. Cancer. 121, 1643-1658 (2007). (Pubitemid 47417279)
12. Xing, D., Tan, W. & Lin, D. Genetic polymorphisms and susceptibility to esophageal cancer among Chinese population (review). Oncol. Rep. 10, 1615-1623 (2003).
13. Lee, J.M., Lee, Y.C., Yang, S. Y., Shi, W. L., Lee, C.J., Luh, S.P. et al. Genetic polymorphisms of p53 and GSTP1, but not NAT2, are associated with susceptibility to squamous cell carcinoma of the esophagus. Int. J. Cancer. 89, 458-464 (2000).
14. Cai, L., Mu, L.N., Lu, H., Lu, Q.Y., You, Y., Yu, S.Z. et al. Dietary selenium intake and genetic polymorphisms of the GSTP1 and p53 genes on the risk of esophageal squamous cell carcinoma. Cancer. Epidemiol. Biomarkers. Prev. 15, 294-300 (2006). (Pubitemid 43342177)
15. Zhang, L., Xing, D., He, Z. & Lin, D. P53 gene codon 72 polymorphism and susceptibility to esophageal squamous cell carcinoma in a Chinese population. Zhonghua. Yi. Xue. Yi. Chuan. Xue. Za. Zhi. 19, 10-13 (2002). (Pubitemid 34151597)
16. Hong, Y., Miao, X.P., Zhang, X.M., Ding, F., Luo, A.P., Guo, Y.L. et al. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer. Res. 65, 9582-9587 (2005). (Pubitemid 41508029)
17. Ge, H., Cao, Y. Y., Chen, L. Q., Wang, Y. M., Chen, Z. F., Wen, D. G. et al. PTEN polymorphisms and the risk of esophageal carcinoma and gastric cardiac carcinoma in a high incidence region of China. Dis. Esophagus. 21, 409-415 (2008).
18. Stephens, M., Smith, N. J. & Donnelly, P. A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 68, 978-989 (2001). (Pubitemid 32289743)
19. Sholom, W., Debra, T. S., Joseph, K. M. & Jack, S. M. Selection of Controls in Case-Control Studies. Am. J. Epidemiol. 135, 1029-1041 (1992).
20. Hu, Z. B., Ma, H. X., Lu, D. R., Qian, J., Zhou, J. N., Chen, Y. J. et al. Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population. Int. J. Cancer. 118, 1275-1278 (2006). (Pubitemid 43185617)
21. Ma, H. X., Hu, Z. B., Zhai, X. J., Wang, S., Wang, X. C., Qin, J. W. et al. Polymorphisms in the MDM2 promoter and risk of breast cancer: A case-control analysis in a Chinese population. Cancer. Lett. 240, 261-267 (2006). (Pubitemid 44093826)
22. Zhang, X. M., Miao, X. P., Guo, Y. L., Tan, W., Zhou, Y. F., Sun, T. et al. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum. Mutat. 27, 110-117 (2006). (Pubitemid 43042973)
23. Xiao, M., Zhang, L., Zhu, W. H., Huang, J., Jiang, H. F., Hu, S. H. et al. Genetic polymorphisms of MDM2 and TP53 genes are associated with risk of nasopharyngeal carcinoma in a Chinese population. BMC. Cancer. 10, 147 (2010).
24. Zhou, G. Q., Zhai, Y., Cui, Y., Zhang, X. M., Dong, X. J., Yang, H. et al. MDM2 promoter SNP309 is associated with risk of occurrence and advanced lymph node metastasis of nasopharyngeal carcinoma in Chinese population. Clin. Cancer. Res. 13, 2627-2633 (2007). (Pubitemid 46788029)
25. Mitsuo, T., Muneaki, S. & Naofumi, N. Expression and prognostic significance of PTEN product protein in patients with esophageal squamous cell carcinoma. Cancer. 94, 1955-1960 (2002).
26. Chang, D., Wang, T. Y., Li, H. C., Wei, J. C. & Song, J. X. Prognostic significance of PTEN expression in esophageal squamous cell carcinoma from Linzhou City, a high incidence area of northern China. Dis. Esophagus. 20, 491-496 (2007). (Pubitemid 47617833)
27. Susan, A. T., Zhao, Z. Z., Lien, L., Krina, T. Z., Nicholas, G. M., Stephen, K. et al. Variants in EMX2 and PTEN do not contribute to risk of endometriosis. Mol. Hum. Reprod. 13, 587-594 (2007). (Pubitemid 47241912)
28. Christopher, A. H., Daniel, O. S., Iona, C., Elena, E.G., Loreall, P., Kathryn, P. et al. Common genetic variation at PTEN and risk of sporadic breast and prostate cancer. Cancer. Epidemiol. Biomarkers. Prev. 15, 1021-1024 (2006).
29. Lynette, S. P., Cheryl, L. T., Alona, M., Sarah, J. P., Thomas, C. T., Graham, C. et al. No association between phosphatase and tensin homolog genetic polymorphisms and colon cancer. World. J. Gastroenterol. 15, 3771-3775 (2009).
30. Ding, J., Gao, Y. Z., Liu, R. Y., Xu, F. & Liu, H. Y. Association of PTEN polymorphisms with susceptibility to hepatocellular carcinoma in a han Chinese population. DNA. Cell. Biol. 30, 229-234 (2011).